Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Arrowhead Pharmaceuticals, Inc. (ARWR) vs ImmunityBio, Inc. (IBRX)

Arrowhead Pharmaceuticals, Inc. and ImmunityBio, Inc. are both Biotechnology companies. Arrowhead Pharmaceuticals, Inc. and ImmunityBio, Inc. are of similar size ($9.3B and $9.2B). ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 16.1%. Arrowhead Pharmaceuticals, Inc. has the higher net margin (−47.8% vs −598.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Arrowhead Pharmaceuticals, Inc. leads on 12 and ImmunityBio, Inc. on 4.

Valuation

Metric ARWR IBRX Biotechnology median
P/E n/m n/m 7.88
P/S 14.12 53.46 11.47
P/B 20.28 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 13.02 56.01 10.73
Earnings yield (3.41%) (11.49%) (28.84%)
Free cash flow yield (0.79%) (3.25%) (23.03%)

Profitability

Metric ARWR IBRX Biotechnology median
Gross margin 100.00% 99.34% 65.16%
Operating margin (33.82%) (151.88%) 0.00%
Net margin (47.79%) (598.56%) 0.00%
Free cash flow margin (11.22%) (173.76%) 0.00%
Return on equity (64.91%) 122.85% (57.72%)
Return on assets (18.32%) (192.58%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARWR IBRX Biotechnology median
Revenue growth (TTM) 16.13% 192.92% 5.64%
EPS growth (last fiscal year) 99.80% 38.71% —
Revenue growth, 5-year CAGR 56.63% 184.76% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARWR IBRX Biotechnology median
Debt to equity 1.85 (0.74) 0.00
Current ratio 5.90 5.72 4.73
Net debt to EBITDA (5.70) (0.97) 0.96

Dividend

Metric ARWR IBRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARWR IBRX Biotechnology median
Market cap 9.33b 9.19b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack